[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Military Hospital 175\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":70},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100652218","continuous-theta-burst-stimulation-for-generalized-anxiety-disorder-100652218",false,"NCT07770919","Continuous Theta Burst Stimulation for Generalized Anxiety Disorder","Effects of Continuous Theta Burst Stimulation Combined With Pharmacotherapy in Generalized Anxiety Disorder","Inclusion Criteria:\n\n* Adults aged 18 to 59 years.\n* Diagnosis of generalized anxiety disorder (GAD; ICD-10 F41.1) according to DSM-5 diagnostic criteria.\n* Hamilton Anxiety Rating Scale (HAM-A) total score \\>18 at screening.\n* Able to understand the study procedures and provide written informed consent.\n\nExclusion Criteria:\n\n* History of epilepsy or seizures.\n* Presence of metal or implanted electronic devices that are contraindications to transcranial magnetic stimulation (TMS), including relevant intracranial metallic implants or cardiac pacemakers.\n* Pregnancy.\n* Acute psychotic symptoms or high suicide risk.\n* Current substance abuse or dependence that may interfere with study participation.\n* Major structural brain lesions that, in the investigator's judgment, may affect study participation or outcome assessment.\n* Any other medical or neurological condition that, in the investigator's judgment, makes participation unsafe or may substantially interfere with study procedures.","ALL","18 Years","65 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"NA","This randomized clinical trial evaluates the effectiveness of continuous theta burst stimulation (cTBS) combined with background pharmacotherapy in patients with generalized anxiety disorder. Participants will be randomly assigned to receive cTBS targeting either the right posterior parietal cortex or the right dorsolateral prefrontal cortex. The study will compare changes in anxiety symptoms between the two treatment strategies and will also assess quality of life, sleep, cognitive function, electroencephalographic measures, and transcranial magnetic stimulation-electroencephalography measures.",[27],"Generalized Anxiety Disorder",[27,29,30,31,32,33],"Continuous Theta Burst Stimulation","cTBS","Transcranial Magnetic Stimulation","Posterior Parietal Cortex","Dorsolateral Prefrontal Cortex","NOT_YET_RECRUITING","2026-08-13",{"date":37,"type":38},"2026-08-18","ACTUAL",{"date":40,"type":21},"2026-08",{"date":42,"type":21},"2028-06",{"name":44,"class":45},"Military Hospital 175","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":68,"leadSponsor":69,"locationsCount":46},"100652099","accelerated-versus-standard-intermittent-theta-burst-stimulation-for-major-depressive-disorder-100652099","NCT07768397","Accelerated Versus Standard Intermittent Theta Burst Stimulation for Major Depressive Disorder","A Randomized Rater-Blinded Trial Comparing Accelerated and Standard Intermittent Theta Burst Stimulation Combined With Pharmacotherapy for Major Depressive Disorder","Inclusion Criteria:\n\n* Age 18 to 65 years.\n* Diagnosis of major depressive disorder (MDD), confirmed by a specialist according to DSM-5 criteria.\n* Hamilton Depression Rating Scale, 17-item version (HAM-D17) score ≥18 at screening\u002Fbaseline.\n* Stable background pharmacotherapy for at least 4 weeks before randomization, with no planned changes in medication regimen or drug class during the intervention period unless clinically required.\n* Right-handed.\n* Able and willing to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* History of epilepsy or seizures, except childhood febrile seizures.\n* Bipolar disorder or psychotic disorder.\n* Acute suicide risk, including HAM-D17 item 3 score ≥3 or clear suicidal intent or behavior.\n* Alcohol or illicit drug abuse or dependence within the previous 6 months.\n* Significant structural brain lesions.\n* Intracranial or head\u002Fneck metallic objects or implants considered unsafe for TMS, including metallic clips, fragments, or cochlear implants.\n* Implanted electronic devices such as pacemakers, implantable cardioverter-defibrillators, or deep brain stimulation devices.\n* Other conditions associated with a high risk of seizure or history of cranial surgery considered unsafe for TMS.\n* Uncontrolled thyroid dysfunction.\n* Severe untreated vitamin D deficiency (\\\u003C20 ng\u002FmL).\n* Acute infection, elevated C-reactive protein, or other clinically significant medical abnormalities that may interfere with study participation.\n* Pregnancy or breastfeeding.\n* Benzodiazepine use exceeding the equivalent of lorazepam 2 mg\u002Fday that cannot be reduced.\n* Use of medications associated with a substantially lowered seizure threshold, including clozapine, high-dose tricyclic antidepressants, or bupropion \\>300 mg\u002Fday.\n* Unstable doses of antiepileptic medications used as mood stabilizers.\n* Previous rTMS treatment.\n* Failure to respond to an adequate course of electroconvulsive therapy (≥8 lifetime sessions).\n* Unable or unwilling to comply with study procedures.",{"count":55,"type":21},80,[24],"This randomized clinical trial aims to compare the effectiveness and safety of accelerated intermittent theta burst stimulation (iTBS) with standard iTBS in adults with major depressive disorder.\n\nParticipants will be randomly assigned to receive either accelerated or standard iTBS targeting the left dorsolateral prefrontal cortex, in addition to pharmacotherapy. The accelerated iTBS group will receive 45 treatment sessions over approximately 15 treatment days, while the standard iTBS group will receive 20 treatment sessions over 4 weeks.\n\nThe primary objective is to compare changes in depressive symptom severity between the two treatment groups from baseline to the end of treatment. Depressive symptoms will be assessed using the 17-item Hamilton Depression Rating Scale (HAM-D17). The study will also evaluate other clinical outcomes, cognitive function, quality of life, sleep quality, neurophysiological measures, and treatment safety.",[59],"Major Depressive Disorder",[61,62,31,63,59],"Intermittent Theta Burst Stimulation","iTBS","Accelerated iTBS","2026-08-12",{"date":66,"type":38},"2026-08-17",{"date":40,"type":21},{"date":42,"type":21},{"name":44,"class":45},""]